ArticleAntiviral research2016
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Article in Antiviral research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.The Journal of infectious diseases · 2024Trial
- Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.The Journal of infectious diseases · 2022Trial
- Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.Antimicrobial agents and chemotherapy · 2018Trial
- Divergent pathogenic mechanisms of influenza A and influenza B viruses.Archives of microbiology · 2026Review
- Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.Pharmacological reports : PR · 2021Article
- Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances.Cold Spring Harbor perspectives in medicine · 2021Review
- Favipiravir in Therapy of Viral Infections.Journal of clinical medicine · 2021Review
- Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis.Frontiers in neurology · 2021Article
- Observational study of people infected with SARS-Cov-2, treated with amantadine.Pharmacological reports : PR · 2020Observational
- Amantadine Treatment for People with COVID-19.Archives of medical research · 2020Article
- Treatments for COVID-19: emerging drugs against the coronavirus.Acta bio-medica : Atenei Parmensis · 2020Review
- Influenza virus polymerase inhibitors in clinical development.Current opinion in infectious diseases · 2019Review
- Structural Insights for Anti-Influenza Vaccine Design.Computational and structural biotechnology journal · 2019Review
- Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.The Journal of infectious diseases · 2018Article
- Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.Antiviral research · 2018Article
- Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.Current medicinal chemistry · 2018Review
- Influenza Virus Infection, Interferon Response, Viral Counter-Response, and Apoptosis.Viruses · 2017Review
- Evolution of Influenza A Virus by Mutation and Re-Assortment.International journal of molecular sciences · 2017Review
- Influenza antivirals currently in late-phase clinical trial.Influenza and other respiratory viruses · 2017Review
- Antiviral therapy for respiratory viral infections in immunocompromised patients.Expert review of anti-infective therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.